For dichotomous outcomes (adverse events), we calculated relative risks (RRs) with 95% confidence intervals (CIs)
Given the high prevalence of NAFLD among people with type 2 diabetes (estimated at 5570%), many patients receiving GLP-1 therapy for diabetes will have concurrent liver disease
Retatrutide impacts muscle movement in the stomach and gut, delaying gastric emptying and facilitating adherence to a meal plan
Semaglutide in 2026 focuses on new indications for cardiovascular protection in obese patients, reducing cardiovascular risk by as much as 20%
The organizations seeing the greatest success are focusing on balanced strategies that combine thoughtful coverage design, clinical support, utilization management, and ongoing evaluation of outcomes
the National Key Basic Research Program of China 2018YFA0507000 (MWW)